Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.35 |
| ▸ | CEPT1 | Q9Y6K0 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225375 | 0.89 | S1PR1 (0.44) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2222186 | 0.89 | S1PR1 (0.48) | S1PR1MAPTLMNARXFP1SGMS2 | |
| SCHEMBL2225593 | 0.88 | S1PR1 (0.52) | S1PR1MAPTLMNARXFP1SGMS2 | |
| SCHEMBL2223451 | 0.88 | S1PR1 (0.45) | S1PR1POLBGAAKMT2AMRGPRX1 | |
| SCHEMBL2228824 | 0.85 | S1PR1 (0.42) | S1PR1MAPTLMNARXFP1APP | |
| SCHEMBL2225216 | 0.84 | S1PR1 (0.69) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL2228881 | 0.84 | ESR1 (0.38) | S1PR1SGMS2POLBGAAKMT2A | |
| SCHEMBL2225306 | 0.84 | S1PR1 (0.54) | S1PR1APPALOX5 | |
| SCHEMBL14486897 | 0.83 | MAP4K4 (0.40) | S1PR1MAPTLMNARXFP1SGMS2 | |
| SCHEMBL2222274 | 0.83 | S1PR1 (0.61) | S1PR1MAPTLMNARXFP1CEPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | claimed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | claimed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | claimed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| EP-2729475-B1 | Carboxylic acid derivatives with an oxazolo[4,5-d]pyrimidine ring | SANOFI SA (FR) | 2015-06-10 | — | — | EP | disclosed |
| EP-2729475-B1 | Carboxylic acid derivatives with an oxazolo[4,5-d]pyrimidine ring | SANOFI SA (FR) | 2015-06-10 | — | — | EP | disclosed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| US-8846690-B2 | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20130023545-A1 | CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| WO-2013004828-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING | SANOFI (FR) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004828-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[4,5-C]PYRIDINE RING | SANOFI (FR) | 2013-01-10 | — | — | WO | disclosed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523960-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086080-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023545-A1 | CYCLOALKYLOXYCARBOXYLIC ACID DERIVATIVES | C3AR1, CCR2, C5 | S1PR1 233/4885MAPT 4798/4885LMNA 1780/4885 |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, CDK2, CCNT2 | S1PR1 1027/4885MAPT 4553/4885LMNA 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.